Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Clinical Trials of Cancer Immunotherapies

Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors

Margaret K. Callahan, Kunle Odunsi, Mario Sznol, John Nemunaitis, Patrick A. Ott, Patrick Dillon, Reva Schneider, Andrew Park, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus and Jedd D. Wolchok
Margaret K. Callahan
Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Yale Cancer Center, New Haven, CT; University of Toledo Medical Center, Toledo, OH; Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Division of Hematology/Oncology, Charlottesville, VA; Mary Crowley Cancer Research Center, Dallas, TX; Ludwig Cancer Research, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kunle Odunsi
Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Yale Cancer Center, New Haven, CT; University of Toledo Medical Center, Toledo, OH; Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Division of Hematology/Oncology, Charlottesville, VA; Mary Crowley Cancer Research Center, Dallas, TX; Ludwig Cancer Research, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Sznol
Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Yale Cancer Center, New Haven, CT; University of Toledo Medical Center, Toledo, OH; Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Division of Hematology/Oncology, Charlottesville, VA; Mary Crowley Cancer Research Center, Dallas, TX; Ludwig Cancer Research, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Nemunaitis
Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Yale Cancer Center, New Haven, CT; University of Toledo Medical Center, Toledo, OH; Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Division of Hematology/Oncology, Charlottesville, VA; Mary Crowley Cancer Research Center, Dallas, TX; Ludwig Cancer Research, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick A. Ott
Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Yale Cancer Center, New Haven, CT; University of Toledo Medical Center, Toledo, OH; Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Division of Hematology/Oncology, Charlottesville, VA; Mary Crowley Cancer Research Center, Dallas, TX; Ludwig Cancer Research, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Dillon
Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Yale Cancer Center, New Haven, CT; University of Toledo Medical Center, Toledo, OH; Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Division of Hematology/Oncology, Charlottesville, VA; Mary Crowley Cancer Research Center, Dallas, TX; Ludwig Cancer Research, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reva Schneider
Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Yale Cancer Center, New Haven, CT; University of Toledo Medical Center, Toledo, OH; Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Division of Hematology/Oncology, Charlottesville, VA; Mary Crowley Cancer Research Center, Dallas, TX; Ludwig Cancer Research, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Park
Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Yale Cancer Center, New Haven, CT; University of Toledo Medical Center, Toledo, OH; Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Division of Hematology/Oncology, Charlottesville, VA; Mary Crowley Cancer Research Center, Dallas, TX; Ludwig Cancer Research, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Schwarzenberger
Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Yale Cancer Center, New Haven, CT; University of Toledo Medical Center, Toledo, OH; Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Division of Hematology/Oncology, Charlottesville, VA; Mary Crowley Cancer Research Center, Dallas, TX; Ludwig Cancer Research, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toni Ricciardi
Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Yale Cancer Center, New Haven, CT; University of Toledo Medical Center, Toledo, OH; Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Division of Hematology/Oncology, Charlottesville, VA; Mary Crowley Cancer Research Center, Dallas, TX; Ludwig Cancer Research, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Macri
Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Yale Cancer Center, New Haven, CT; University of Toledo Medical Center, Toledo, OH; Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Division of Hematology/Oncology, Charlottesville, VA; Mary Crowley Cancer Research Center, Dallas, TX; Ludwig Cancer Research, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aileen Ryan
Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Yale Cancer Center, New Haven, CT; University of Toledo Medical Center, Toledo, OH; Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Division of Hematology/Oncology, Charlottesville, VA; Mary Crowley Cancer Research Center, Dallas, TX; Ludwig Cancer Research, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralph Venhaus
Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Yale Cancer Center, New Haven, CT; University of Toledo Medical Center, Toledo, OH; Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Division of Hematology/Oncology, Charlottesville, VA; Mary Crowley Cancer Research Center, Dallas, TX; Ludwig Cancer Research, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jedd D. Wolchok
Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Cancer Institute, Buffalo, NY; Yale Cancer Center, New Haven, CT; University of Toledo Medical Center, Toledo, OH; Dana-Farber Cancer Institute, Boston, MA; University of Virginia, Division of Hematology/Oncology, Charlottesville, VA; Mary Crowley Cancer Research Center, Dallas, TX; Ludwig Cancer Research, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A006 Published February 2019
  • Article
  • Info & Metrics
Loading
Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY

Abstract

Durvalumab (durva) is a human IgG1 monoclonal antibody (mAb) that blocks programmed cell death ligand-1 (PD-L1). Tremelimumab (treme) is a human IgG2 mAb inhibitor of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). Blocking these checkpoints can result in antitumor activity in some solid tumors. The targets for durva and treme are non-redundant, providing sound rationale for clinical testing of the combination.This is an ongoing phase 1, multicenter, open-label study (NCT01975831) with a dose escalation (3+3 design) and subsequent expansion phase. Patients with renal cell carcinoma (RCC), cervical (CC), colorectal (CRC), non-triple-negative breast (NTNBC), or ovarian (OC) cancer are included in the expansion phase. The protocol excludes patients who had prior exposure to anti-CTLA-4 or anti-PD-1/PD-L1 antibodies. Primary objectives are safety/tolerability and identification of maximum tolerated dose (MTD) of the combination. Secondary objectives include tumor response, progression-free survival (PFS), and overall survival (OS). The intent-to treat (ITT) analysis set includes all patients who received at least one dose of durva or treme and had the baseline and at least one post-baseline tumor assessment.As of 11 May 2018, 104 patients were treated (73.1% female; median age: 56 (30 to 80) years. Durva 1500 mg every 4 weeks (Q4W) X 12 and treme 75 mg Q4W X 4 was the regimen used for opening the expansion phase (n = 82 patients). The majority of treatment-related adverse events (TRAEs) for all patients were Grades 1 and 2. TRAEs ≥ Grade 3 were reported in 17 (16.3%) patients; the majority were diarrhea/colitis (n = 6) and abnormal liver function tests (n = 4) and responded to established treatment algorithms. There was 1 Grade 5 TRAE: multi-organ failure. Fifteen (14.4%) patients experienced TRAEs leading to treatment discontinuation; the majority were diarrhea/colitis (n = 6) and abnormal liver function tests (n = 5). No new toxicities were identified. Tumor response by immune-related Response Criteria (irRC) was assessed by tumor type in the ITT analysis set for all cohorts included in the expansion phase; the follow-up period was at least 12 months. Best overall responses (complete response (irCR), partial response (irPR) and stable disease (irSD)) are presented by tumor type. For OC (n = 27): irCR = 0, irPR = 2 (7.4%), irSD = 10 (37%); for CRC (n = 18): irCR = 1 (5.6%), irPR = 1 (5.6%), irSD = 2 (11.1%); for NTNBC (n = 16): irCR = 0, irPR = 1 (6.3%), irSD = 2 (12.5%); for RCC (n = 19): irCR = 0, irPR = 3 (15.8%), irSD = 11 (57.9%); and for CC (n = 16): irCR = 1 (6.3%), irPR = 3 (18.8%), irSD = 4 (25%) patients. PD-L1 status is not yet available. MSI status was collected retrospectively for patients with CRC; in this group, the patient with irPR had MSI-high status, and the MSI status of the patient with irCR is unknown. PFS and OS rates will be presented at the meeting. In conclusion, the durva and treme combination has a manageable safety profile, with evidence of clinical activity. These data support continued study of the combination therapy.

Citation Format: Margaret K. Callahan, Kunle Odunsi, Mario Sznol, John Nemunaitis, Patrick A. Ott, Patrick Dillon, Reva Schneider, Andrew Park, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus, Jedd D. Wolchok. Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A006.

  • ©2019 American Association for Cancer Research.
Previous
Back to top
Cancer Immunology Research: 7 (2 Supplement)
February 2019
Volume 7, Issue 2 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Margaret K. Callahan, Kunle Odunsi, Mario Sznol, John Nemunaitis, Patrick A. Ott, Patrick Dillon, Reva Schneider, Andrew Park, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus and Jedd D. Wolchok
Cancer Immunol Res February 1 2019 (7) (2 Supplement) A006; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A006

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Margaret K. Callahan, Kunle Odunsi, Mario Sznol, John Nemunaitis, Patrick A. Ott, Patrick Dillon, Reva Schneider, Andrew Park, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus and Jedd D. Wolchok
Cancer Immunol Res February 1 2019 (7) (2 Supplement) A006; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A006
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Trials of Cancer Immunotherapies

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
Show more Clinical Trials of Cancer Immunotherapies

Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement